Healthcare entity

Xiao Ruiping

Person

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. Source depth averages 10 original sources per story, versus 3.3 across the same-window beat baseline.

Last mentioned: Mar 25, 2026

Entity pulse

Recent coverage · Xiao Ruiping

1 story
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Xiao Ruiping

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. Source depth averages 10 original sources per story, versus 3.3 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.6. Xiao Ruiping appears in 1 tracked Healthcare story from March 25, 2026.

Stories tracked
1
Sources per story
10

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Xiao Ruiping. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Phase III Initiation

    First patient dosed at Peking Union Medical College Hospital in China.

  2. Regulatory Designations

    FDA grants Fast Track and NMPA grants Breakthrough Therapy status.

  3. Phase II Data Publication

    Results showing efficacy without hormonal side effects published in The Lancet.

Stories mentioning Xiao Ruiping 1

Xiao Ruiping is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.